

# ASHI

## Laboratory Manual

### Edition 4.2

Editor: J. C. Rosenberg, MD, PhD

**Supplement 2**

**New/Revised Procedures**

**January 2007**

#### In this Supplement....

Procedure	Volume	Chapter
<input checked="" type="checkbox"/> Removal of Interfering Substances from Sera and Cells for Screening and Crossmatching: Thymoglobulin Removal; Removal of Therapeutic Antibodies with Lymphocyte Cell Lines; Pronase Treatment of B Lymphocytes	I	I.B.7.1
<input checked="" type="checkbox"/> Strategies To Consider When Confronted With Interfering Therapeutic Substances in Patient Samples	I	I.B.7.2
<input checked="" type="checkbox"/> The Quality Assurance/Improvement Program (Revised)	I	III.A.1
<input checked="" type="checkbox"/> Primers and Probes: Design and Labeling for Detection of Nucleic Acids (Revised)	II	V.B.1
<input checked="" type="checkbox"/> KIR Genotyping by SSP	II	V.E.4.1
<input checked="" type="checkbox"/> MICA Allele-Level Typing by SBT	II	V.E.5.1
<input checked="" type="checkbox"/> DSA Assay: A Donor-Specific Solid-Phase Method for Detecting Anti-MHC Antibodies Using XMap™ (Luminex™) Technology	II	VI.B.5.1
<input checked="" type="checkbox"/> Evaluation of the Flow Crossmatch Using the MESF (Molecules of Equivalent Soluble Fluorochrome) Method	II	VI.B.6.1
<input checked="" type="checkbox"/> CD34 Enumeration	II	VI.C.3.1